Nedaplatin: a cisplatin derivative in cancer chemotherapy

Abstract

Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80–100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin. In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered. Ishibashi’s formula, ie, DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47, would be predictable and useful for estimating the individual dose of nedaplatin. Several Phase II studies have suggested that nedaplatin might be a useful second analog, especially for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer, or urothelial cancer. Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world. Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.

Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung

“…22,26) Nedaplatin is a cisplatin derivative designed to reduce cisplatin toxicity and has potential antitumor effects against SCC in various organs. 10,27) Its use in combination with irinotecan confers a prognostic benefit for patients with SCC. 11) However, hematological adverse events are problematic in nedaplatin-based chemotherapy.…”

Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy

“…Nedaplatin, a second-generation cisplatin analog, has an identical effectiveness to cisplatin, with fewer renal and gastrointestinal toxicities (24,25). Although nedaplatin is cross-resistant to cisplatin in the histoculture drug response assay, nedaplatin has a higher inhibitory effect of tumor growth index than cisplatin in specimens from UC patients (26,27).…”

Future directions in esophageal cancer therapy

“…Nedaplatin is a cisplatin analog that has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity (19)(20)(21).…”